The Institute of Cancer Research has welcomed NICE’s recommendation of talazoparib in combination with enzalutamide for adults with metastatic prostate cancer, providing a new treatment option for ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果